Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
REDWOOD CITY, Calif. and SHANGHAI, China , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877;...
-
REDWOOD CITY, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright...
-
REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data...
-
SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc....
-
REDWOOD CITY, Calif., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Aug. 26, 2021, the compensation committee...
-
– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone – - Data support the use of toripalimab with chemotherapy as first-line therapy...
-
SHANGHAI, China, and REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
-
–1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA — – CHS-201 (Lucentis® biosimilar) BLA submitted to FDA – –CHS-1420...
-
REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after...
-
REDWOOD CITY, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of...